The initial success of the copyright undeniably reshaped the medication landscape, but investing in companies primarily reliant on off-patent versions presents a complex picture. Although early returns were significant, the expiration of patents and the emergence of discounted alternatives have weakened the customer base. Thus, a thorough analys… Read More